Phaseline

Targets › ATP7A

ATP7A (Copper-transporting ATPase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2031.

ATP-driven copper (Cu(+)) ion pump that plays an important role in intracellular copper ion homeostasis. Within a catalytic cycle, acquires Cu(+) ion from donor protein on the cytoplasmic side of the membrane and delivers it to acceptor protein on the lumenal side. (UniProt, Q04656)

Open in Phaseline: the race on ATP7A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dartmouth-Hitchcock Medical CenterTetrathiomolybdate (TM)
Copper-lowering agent that forms stable copper-molybdenum clusters, sequestering copper an
ATP7A, ATP7BPhase 1Triple Negative Breast CancerJun 2031

Conditions

Triple Negative Breast Cancer (1)

Modalities

mixed (1)

Companies

Dartmouth-Hitchcock Medical Center (1)

Related targets

ATP7B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.